TD Cowen Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)

TD Cowen analyst Ritu Baral reiterated a Buy rating and $9.00 price target on Milestone Pharmaceuticals (NASDAQ: MIST).

The analyst commented, "MIST's China-partner, Ji Xing, released positive Ph3 topline data of etripamil in pSVT. A stat sig greater % of pts treated w/ etripamil converted to normal sinus rhythm within 30 mins vs PBO (HR=3; p<0.001). Safety/tolerability were consistent w/ prior etripamil trials. We continue to believe in etripamil's US approvability and commercial potential, and estimate peak US sales of $441M in 2033."

For an analyst ratings summary and ratings history on Milestone Pharmaceuticals click here. For more ratings news on Milestone Pharmaceuticals click here.

Shares of Milestone Pharmaceuticals closed at $1.46 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)